Dynavax Technologies

DVAX

Market cap $1.26B

EMERYVILLE, Calif. , Nov. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd at 2:10 p.m.

Dynavax Technologies Corporation ( DVAX ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul Cox - VP of Investor Relations & Corporate Communications Ryan Spencer - CEO & Director Donn Casale - Senior VP & Chief Commercial Officer Robert Janssen - Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs Kelly MacDonald - Senior VP & CFO Conference Call Participants Matthew Phipps - William Blair & Company L.L.C., Research Division Philip Nadeau - TD Cowen, Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to the Dynavax Technologies Third Quarter 2025 Financial Results Conference Call.

Dynavax Technologies (DVAX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.

HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; r eiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 million Board of Directors authorizes new $100 million share repurchase program  Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's novel oral COVID-19 vaccine program, expanding pipeline opportunities Conference call today at 4:30 p.m. ET/1:30 p.m.

Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options Vaxart to continue leading and funding development through Phase 2b completion and End of Phase 2 meeting with FDA ; Dynavax to receive exclusive, worldwide license and right to assume responsibility for continued clinical development and commercialization following Phase 2b clinical development Vaxart will receive a $25 million upfront payment and a $5 million equity investment from Dynavax, along with additional potential milestone-based payments and royalties contingent on Dynavax advancing the program post-Phase 2b data readout EMERYVILLE, Calif. and SOUTH SAN FRANCISCO, Calif.

EMERYVILLE, Calif. , Oct. 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close.

Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profile Newly presented data outline robust polyfunctional CD4+ T-cell responses in Z-1018 arms Company initiates Part 2 of Phase 1/2 head-to-head versus Shingrix in adults 70 years and older EMERYVILLE, Calif. , Oct. 21, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today presented positive topline data from Part 1 of its randomized, observer-blinded, active-controlled Phase 1/2 clinical trial of Z-1018, the Company's novel shingles vaccine candidate, in a late-breaker session at IDWeek 2025.

Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.

EMERYVILLE, Calif. , Aug. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd at 4:30 p.m.

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in early-to-mid-stage study.